BOVN.F Stock Overview
A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.70 |
| 52 Week High | SEK 6.63 |
| 52 Week Low | SEK 2.98 |
| Beta | 0.48 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOVN.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how BOVN.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BOVN.F performed against the US Market.
Price Volatility
| BOVN.F volatility | |
|---|---|
| BOVN.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BOVN.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BOVN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 89 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma.
BioInvent International AB (publ) Fundamentals Summary
| BOVN.F fundamental statistics | |
|---|---|
| Market cap | US$249.15m |
| Earnings (TTM) | -US$3.84m |
| Revenue (TTM) | US$27.21m |
9.2x
P/S Ratio-64.9x
P/E RatioIs BOVN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOVN.F income statement (TTM) | |
|---|---|
| Revenue | SEK 295.46m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 295.46m |
| Other Expenses | SEK 337.13m |
| Earnings | -SEK 41.66m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 27, 2022
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 100.00% |
| Net Profit Margin | -14.10% |
| Debt/Equity Ratio | 0% |
How did BOVN.F perform over the long term?
See historical performance and comparison